Background Analysis: US FDA Advisory Committee to Review Secukinumab by Novartis for Psoriasis– OCT 20, 2014 (DODAC)
See the SAC Tracker report
Background Analysis: US FDA Advisory Committee to Review Secukinumab by Novartis for Psoriasis– OCT 20, 2014 (DODAC)
See the SAC Tracker report